PET and SPECT in the management of lung cancer.
Lung cancer is the leading cause of cancer deaths in men and women. Most recently in 2001, the Health Care Financing Administration has expanded Medicare coverage for positron emission tomography (PET) to include the diagnosis, staging, and restaging of lung cancer. This review discusses the current metabolic imaging techniques, including the role of PET, single-photon emission computed tomography (SPECT), and the new hybrid PET in the diagnosis, staging, and treatment of lung cancer. The technological advantages, disadvantages, and benefits are compared. PET has the highest detection efficiency than gamma camera based devices. PET when merged with computed tomography (CT) forms the powerful hybrid PET-CT system, capable both of metabolic and anatomic imaging. Clinical imaging pathways based on these newer modalities for the management of lung cancer are proposed. Technological advances in metabolic imaging linked with therapy driven protocols and outcomes may further provide cutting edge modalities that positively impact on dismal lung cancer mortality statistics.
Sarinas
Priscilla S A
PS
Division of Pulmonary, Critical Care, and Sleep Medicine, Veteran's Affairs Palo Alto Health Care System and Stanford University School of Medicine, Palo Alto, California 94304, USA. sarinas@santord.edu
Chitkara
Rajinder K
RK
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D009367:Neoplasm Staging; D011859:Radiography; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D019788:Fluorodeoxyglucose F18